
New phenotypic data from Simons Searchlight participants were recently added to SFARI Base. This release includes data from individuals with 94 gene changes and 15 copy number variants known to be connected to autism.
New phenotypic data from Simons Searchlight participants were recently added to SFARI Base. This release includes data from individuals with 94 gene changes and 15 copy number variants known to be connected to autism.
SFARI is pleased to announce that it intends to fund three collaborative projects in response to the 2023 Cross-Species Studies of ASD request for applications.
This year’s new cohort of National Academy of Medicine members includes two investigators funded by the Simons Foundation Autism Research Initiative (SFARI). Election to the academy “recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.”
A number of presentations will be given by SFARI Investigators at Neuroscience 2023, the annual meeting of the Society for Neuroscience.
SFARI is pleased to announce that it intends to fund 9 grants in response to the 2023 Winter Pilot Award request for applications.
In order to advance the frontiers of research in science, the Simons Foundation recognizes the need for a diversity of ideas and perspectives contributing to the scientific enterprise. To that end, the foundation supports talented early-career scientists from diverse and underrepresented backgrounds as they transition from mentored training to independent research positions.
The Simons Foundation is pleased to announce this year’s recipients of its prestigious independence awards. The 13 fellows will receive support as they transition from mentored training to independent research positions.
Phenotypic data from 328,973 participants enrolled in SPARK, including 132,138 individuals with ASD, are now available to approved researchers. Genomic data also is available for 116,693 SPARK participants, specifically 106,744 (44,304 ASD) with whole exome sequencing, and 12,519 (3,575 ASD) with whole genome sequencing. A total of 2,570 individuals have both.